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Abstract 
Objective: The aim of this study was to determine the outcome of antiepileptic drug (AED) 
treatment based on seizure freedom, pharmacovigilance reports and effects of concomitant 
medication on the central nervous system (CNS) of adult epileptic patients registered in the 
East-Hungarian Epilepsy Database. 
Methods: Prospective cross-sectional database was compiled from outpatient files between 
1992 and 2011. 
Results: The majority of 1282 treated patients were on monotherapy 894 patients (70%), 286 
(22%) on bitherapy and 102 (8%) on polytherapy. Of all treated patients, seizure freedom was 
achieved by 603 (47%). Among the seizure free patients 464 (77%) were on monotherapy, 
115 (19%) on bitherapy and only 24 (4%) on polytherapy. The overall rate of adverse drug 
reactions (ADRs) was 16.2%. From patients on AED, 279 (22%) took concomitant drugs 
acting on the CNS. In a logistic regression model, other CNS-related drugs and a number of 
prescribed antiepileptic drugs had a significant influence on the desired outcome of seizure 
freedom. On comparing the Proportional Reporting Ratio and 95%CI of older and newer 
AEDs, no significant superiority of newer AEDs was detected. 
Conclusion: Careful drug selection for epileptic patients must be highlighted in order to 
improve outcome, reduce ADRs and improve patient compliance. 
Keywords: epilepsy, database, antiepileptic drug treatment, seizure freedom, adverse drug 
reaction, pharmacovigilance  
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1. Introduction 
Epilepsy is a complex issue that has an impact on the patients’ quality of life [1]. Treating 
epilepsy means a life-time treatment, so real-life studies are important [2]. Uncontrolled 
seizures may increase the hospitalization rate even up to 35% [3]. Since financial support of 
antiepileptic treatment varies between countries it is important to have local databases. For 
tolerability and long term effectiveness these databases are also useful [4]. Camfield 
concluded that population-based research with large grouping had a considerable impact on 
the understanding of epilepsy [5]. Many factors, including comorbidities and their medication, 
could influence the outcome of antiepileptic treatment [6]. A number of drugs can predict 
patient adherence [7, 8]. Until new methods are available to predict the outcome, there is only 
a “reasonable chance” of good outcome, which can be described using data from ongoing 
treatments [9]. Alternative monotherapy and early add-on therapy showed the same 
effectiveness and adverse drug reaction (ADR) profile among persistent focal seizure patients 
in France [10]. 
ADRs are commonly experienced with antiepileptic drug (AED) treatment. Most of the ADRs 
are mild and tolerable, but severe effects have also been reported [11]. Due to long duration of 
treatment, various ADRs are seen, which requires change of medication and monitoring. 
The prevalence of ADRs is described using Proportional Reporting Ratio (PRR) and Reported 
Odds Ratio (ROR) beside basic characteristics [12]. PRR means the portion of spontaneous 
report for a specified drug with certain ADR divided by the corresponding proportion of other 
drugs or group of drugs. PRR can be used as a direct measure of the strength of the signal and 
it can also be used to determine unexpectedness relative to the background of the rest of the 
database [13, 14]. ROR provides additional information over PRR, which can be important in 
evaluating the link between ADRs and drugs. Furthermore, ROR allows the estimation of 
relative risk and removal of biases [12]. 
Using PRR and ROR, signal of disproportionate reporting (SDR) can show the association 
between drug-event pair in the database which can be generated from spontaneous adverse 
drug reaction reporting systems based on European Medicines Agency (EMA) criteria [15]. 
The purpose of this study was to investigate the basic characteristics of patients registered in 
our East-Hungarian epilepsy database, the outcome of AED treatment, the effects of 
concomitant medication on the central nervous system (CNS), and pharmacovigilance report 
using PRR, ROR and SDR. 
2. Methods 
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2.1 Database 
Debrecen Epilepsy Database was created in order to analyse the data of patients through their 
case histories from out-patient files, covering the period between 1992 and 2011 in a cross-
sectional view. In our database we registered all of the adult patients (2152) who were 
referred to our out-patient or in-patient department by general practitioners or other out-
patient clinics (approximately 108 patients/year). Our epilepsy out-patient unit provides care 
for patients from 16 years of age. The majority of the patients are from Debrecen (approx. 
70%) and the remainder are referred from 3-4 counties (700 000 catchment area). 
We excluded those who had no seizures at all or their seizures were related to alcohol 
dependency. Most of the patients with alcohol problems understated or disclaimed alcohol 
consumption. Due to their poor adherence to instructions and treatment we excluded them 
from the final analysis. Eventually, 1528 patients with epileptic seizures were included in the 
database. Patients were coded with epilepsy diagnoses in accordance with the International 
Classification of Diseases by the World Health Organization [16]. 
Data were obtained from every patient at the first and subsequent out-patient visits, also from 
past medical records as well as family members. We collected 60 parameters per patient. 
Among others, the following data were entered into the database: gender, age at the first visit, 
age at the onset of epilepsy, family history of epilepsy, risk factors of epilepsy (including 
febrile convulsions), relevant details of past medical and neurological history such as 
congenital disorder, type of delivery, miscarriage, causes of symptomatic epilepsy, 
neurological and psychiatric comorbidities, influence of meteorological factors, classification 
of present and past seizures, frequency of each seizure type, EEG and imaging findings, past 
and present antiepileptic drug treatment, further drugs acting on the CNS, ADR and drug 
interactions, etc. We defined childhood between 0-14 years and adolescence between 15-20 
years. Concomitant drugs acting on the CNS were prescribed by a neurologist / epileptologist, 
psychiatrist or general practitioner. During each visit, we monitored suicidal intent and 
behaviour and, if required, the Beck Depression Inventory (BDI) was used for measuring the 
severity of depression. Serum electrolyte levels, liver and kidney functions were evaluated 
regularly. In addition, therapeutic drug monitoring (TDM) was also required (valproate 
[VPA], carbamazepine [CBZ], phenytoin [PHT] continuously available, and lamotrigine 
[LTG] for some patients). In the current study, we focused on the effectiveness of current 
antiepileptic therapy, further drugs acting on the CNS and pharmacovigilance report. 
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All the patients with potential drug or alcohol-induced, psychogenic and heart-related seizures 
were excluded. The patients were classified as suffering from generalized, focal and unknown 
seizures according to the ILAE definition [17, 18]. 
The epileptologists chose the best treatment modality for each patient. In most cases the first 
two AEDs were prescribed as monotherapy. If monotherapy had failed a combination was 
considered. Doses were built up very carefully in accordance with the summary of product 
characteristics up to a medium dose range, and were further increased up to the maximally 
tolerated dose in case seizures occurred repeatedly. When needed, TDM (if available) was 
performed and assessed to guide dosage changes and, also, to test patient compliance. A 
patient was considered nonadherent (non-compliant) if he or a relative reported not taking 
their medication, the patient has changed the prescribed daily dose intentionally or TDM has 
revealed unmeasurable or very low plasma concentration of AED. 
According to ILAE definition seizure freedom meant at least three times the interval of the 
longest previous interseizure duration (determined from seizures occurring within the past 12 
months, or in any 12-month-period, whichever was longer) [19]. We followed up the patients’ 
status for many years (until closing the database), to determine whether their seizures truly 
came under control. Drug resistant epilepsy was defined as failure of adequate trials of two 
tolerated, appropriately chosen and used antiepileptic drug schedules (either as monotherapies 
or in combination) to achieve sustained seizure freedom [19]. The seizure freedom and 
current therapy were determined at the last follow-up visit. 
On the strength of patients’ report, adverse drug reactions were recorded in the patients’ files 
after the physician considered their causality. On the basis of the above, our database stores 
individual case safety reports (ICSRs). 
We used the following criteria for generating a signal according to EudraVigilance [15, 20]: 
a) When the PRR is displayed with its 95% confidence interval: 
- the lower bound of the 95% confidence interval is greater than or equal to one 
- the number of individual cases is greater than or equal to three 
b) When the PRR is displayed with χ2 statistic: 
- the PRR > 2 
- χ2> 4 
- the number of individual cases is greater than or equal to three. 
Ethical approval was obtained from the Regional and Institutional Research Ethics Committee 
(DEOEC RKEB/IKEB: 2584A-2007). 
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2.2 Statistics 
Statistical analysis was carried out using the SPSS for Windows 19.0 (SPSS Inc. Chicago, 
USA) and Microsoft Office Excel 2007. 
Two-sample T test, and F test were used to analyse our patients’ data. Categorical variables 
were assessed using Pearson χ2 test and logistic regression. 
As per standard pharmacovigilance practices, the values of the PRR and ROR were computed 
using 2x2 contingency table [13]. 
Significant differences were considered if p<0.05.  
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3. Results 
3.1 Basic characteristics of patients 
We registered 2152 patients in our database (Figure 1). We excluded all the patients who had 
no epileptic seizures (heart-related, pulmonological and other disorders were detected in 375 
patients). Alcohol consumption or withdrawal of alcohol caused seizures in 249 patients. 
Figure 1 Flow chart. Investigation and treatment of patients registered in the Epilepsy 
Database 
 
 
Processed out-
patient files
Total N= 2152
Confirmed one or 
more seizures
N= 1528
Patients with 
epilepsy
N= 1372
Patients on AED(s)
N= 1282
Patients on 
monotherapy
N= 894
Seizure freedom
N= 464
Not seizure free
N= 430
Patients on 
bitherapy
N= 286
Seizure freedom
N= 115
Not seziure free
N= 171
Patients on 
polytherapy
N= 102
Seizure freedom
N= 24
Not seizure free
N= 78
Seizure free 
patients without 
AED treatment
N= 90
Occasional seizure 
(provoked, 
metabolic..)
N= 156
Revealed no seizure
N= 375
Alcoholics with 
seizure
N= 249
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We registered 1528 patients (760 males and 768 females) with one or more epileptic seizures. 
Mean age was 48.28 ±18.18 years with no significant difference (male: 49.25±17.9, female: 
47.33±18.42 years). Patient age at first seizure showed male dominancy in adulthood. A 
significantly different sex ratio could be seen in the childhood onset groups (p=0.03; females 
were in majority in such groups). Approximately 1/5 and 1/6 of patients had their first seizure 
in childhood and adolescence, respectively. Cumulative incidence of epilepsy by age at the 
first registration and current age was parallel above 20 years and the number of the registered 
patients decreased by age after 50 years. 
During the study period 106 (7%) patients died due to comorbidities but only three patients’ 
deaths were related to epilepsy; two of them had epileptic status. 
Recurring seizures were observed in 1372 (89.8%) patients so, in accordance with the ILEA 
definition, these patients had epilepsy, and 156 (10.2%) patients had provoked and/or 
metabolic failure-induced seizures. While 856 (56%) of the patients had generalized seizures, 
602 (39.4%) had focal seizures (no significant difference in gender between seizure type v. all 
patients; p= 0.20 and p= 0.27 respectively) and 70 (4.6%) of the patients had unknown 
seizures. Gender ratios (male/female) were 1.09 in the generalized seizure group and 0.88 in 
focal seizure group (gender was significantly different, p=0.04). 
Family history was positive for epilepsy in 107 (7.8%) out of 1372 patients. Idiopathic 
epilepsy affected 228 (16.6%) patients whereas symptomatic epilepsy was confirmed in 574 
(41.8%) patients (stroke: 185 [32.2%], head injury: 155 [27%], congenital disorders: 76 
[13.2%], tumour: 74 [12.9%], CNS infection: 57 [9.9%], other disorders such as cerebral 
atrophy or arachnoid cyst: 27 [4.7%]). Cryptogenic epilepsy and new onset epilepsy were 
diagnosed in 570 (41.2%) and 686 (50%) patients, respectively. 
3.2 Treatment characteristics 
Among the recruited patients, 1282 (93.4%) took AEDs but 90 (6.6%) did not due to 5-10 
years of seizure free status (Figure 1). 
According to the last follow-up visit 894 (70%) of the patients were on monotherapy, 286 
(22%) on bitherapy and 102 (8%) on polytherapy (Table 1). Being on monotherapy, the 
majority of patients took CBZ, VPA and LTG (449 [50.2%], 197 [22%] and 118 [13.2%], 
respectively). PHT and phenobarbital (PB) prescriptions amounted to only 11 (1.2%) and 4 
(0.4%) respectively. Newer AEDs were taken by 229 patients (25.6%); oxcarbazepine (OXC; 
61 patients [6.8%]) and levetiracetam (LEV; 35 patients [3.9%]) were the most commonly 
prescribed ones in this group.  
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Table 1 Antiepileptic treatment and its relationship with adverse drug reaction (ADR) 
Type of therapy 
All patients 
(N=1282) 
Male 
(N=608) 
Female 
(N=674) 
p-value 
Monotherapy 894 (69.7%) 427 (33.3%) 467 (36.4%) 0.91 
ADR 147 (16.4%) 51 (5.7%) 96 (10.7%) 0.003* 
Bitherapy 286 (22.3%) 137 (10.7%) 149 (11.6%) 0.94 
ADR 53 (18.5%) 18 (6.3%) 35 (12.2%) 0.06 
Polytherapy 102 (8%) 44 (3.4%) 58 (4.6%) 0.46 
ADR 24 (23.5%) 9 (8.8%) 15 (14.7%) 0.65 
 
*: significance between males and females. 
ADR is significantly higher in females than in males using AED in monotherapy (p=0.003). 
 
Among the patients on monotherapy (N=894), 464 patients (52%) took AEDs which had an 
enzyme-inducing effect on drug metabolizing enzymes (CYPs systems), 197 patients (22%) 
were prescribed with enzyme inhibiting AEDs, 62 patients (7%) used AEDs with both effects 
on enzyme systems and in 171 patients (19%) the AED had no effect on liver metabolizing 
systems. 
Bitherapy included 15 AEDs prescribed in 45 different combinations. The most commonly 
used combinations were CBZ-VPA (66 patients [23.1%]), CBZ-LTG (29 patients [10.1%]), 
CBZ-LEV (28 patients [9.8%]), VPA-LTG (25 patients [8.7%]), CBZ-clonazepam (CZP; 22 
patients [7.7%]), CBZ- gabapentin (GBP; 14 patients [4.9%]), LEV-OXC (13 patients 
[4.5%]), VPA-LEV (11 patients [3.8%]), LTG-LEV (8 patients [2.8%]) and VPA-CZP (8 
patients [2.8%]). Old-old, old-new and new-new AED combinations were prescribed for 118 
(41%), 133 (47%) and 35 (12%) patients, respectively. The prevalence of newer AEDs use 
was 35.5%. As for the number of participants, there was no significant difference between 
males and females on mono-, bi-, or polytherapy. 
The enzyme inhibitor (only VPA) played the same role in mono-, bi-, and polytherapy (197 
[22%], 122 [21.3%], and 65 [19.4%], respectively). In both groups on bi- and polytherapy, the 
second choice of AEDs was for an enzyme inducer and/or inhibitor. 
Seizure freedom was achieved in 47% of all treated patients (Table 2). The overall seizure 
freedom was 693 (50.5%) including those patients (90, 6.6%) who did not take AEDs because 
of long-term seizure freedom. We calculated seizure freedoms in patients with generalized 
and partial epilepsy, 396 (52.1%) and 283 (49.8%), respectively. Seizure freedom was 48 
(45.5%) among the patients with positive family history of epilepsy. In the subgroup 
idiopathic, symptomatic, cryptogenic and new onset epilepsy seizure freedom was 125 (55%), 
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258 (45%), 288 (50.5%) and 340 (49.5%) respectively. Differences were not significant. From 
them 584 (96.9%) patients were seizure free for more than one year, eight patients were 
seizure free less than six months (1.3%) and 11 (1.8%) patients were seizure free more than 
six months but less than one year. Among the seizure free patients 77% of the patients were 
given monotherapy, 19% received bitherapy and only 4% were on polytherapy. More than 
half of the patients receiving only one type of AED were seizure free. When taking a 
combination of three or more AEDs, only 24% of patients were seizure free. The proportion 
of seizure free patients was nearly the same in monotherapy, bitherapy and polytherapy in 
both genders. There was no significant difference between genders. 
 
Table 2 Effectiveness of AED treatment using monotherapy, bitherapy and polytherapy, 
comparing males and females, and seizure freedom 
Type of 
therapy 
Number and 
percentage 
(%) of 
patients 
taking 
AED(s) 
Number 
and 
percentage 
(%) of all 
seizure free 
patients 
Percentage 
(%) of 
seizure 
free 
patients 
within 
each 
group 
p1-
value 
Number and 
percentage 
(%) of 
seizure free 
males 
Number and 
percentage 
(%) of seizure 
free females 
p2-
value 
Monotherapy 894 (69.7) 464 (77) 52 0.60 221 (47.6) 243 (52.4) 0.08 
Bitherapy 286 (22.3) 115 (19) 40 0.92 56 (48.7) 59 (51.3) 0.20 
Polytherapy 102 (8) 24 (4) 24 0.94 12 (50) 12 (50) 0.50 
Total 1282 (100) 603 (100) 47 NA 341 (49.2) 352 (50.8) NA 
 
p1: significance between all seizure free patients and all patients taking AED(s). 
p2: significance between seizure free male and female patients. 
NA: not applicable 
 
We used logistic regression model in order to analyse what kind of factors influenced seizure 
freedom, where seizure freedom was the dependent variable and gender, age group, type of 
seizure, other drugs acting on the CNS, number of AEDs and ADR were the independent 
variables. In this model, the number of AEDs and other drugs acting on the CNS had a 
significant impact on seizure freedom (all p<0.05). No link was revealed with gender, age 
group, type of seizure or ADR. Increase in the number of AEDs and the presence of other 
drugs acting on the CNS reduced the chance of seizure freedom significantly (p<0.05). 
Nonadherence was associated with 12% of patients (154). 
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3.3 Adverse drug reaction (ADR) 
Patients on AED monotherapy exhibited fewer ADRs than the patients on bi- or polytherapy. 
The differences between males and females were significant in the monotherapy group 
(p=0.003) (Table 1). There was an unfavourable but not significant trend in the occurrence of 
ADRs among female patients on bitherapy. 
ADRs (incidence: 16.2%) were reported by 247 patients (male: 89 [36%], female: 158 
[64%]). The vast majority (195; 80%) of the patients had one ADR and while 52 (20%) 
suffered two or more ADRs. The majority of patients with ADR were female. The differences 
were significant (1 ADR p= 0.008; 2 ADRs p= 0.009). Among those having ADRs, the 
number of seizure free patients and those with recurrent seizures were not significantly 
different. 
Altogether 326 different ADRs were reported due to AED by our 247 patients. Most of them 
were women (217 [66.6%] reports from women, and 109 [33.4%] from men). The most 
common AEDs causing ADR were CBZ (42%; male vs. female, 37.2% vs. 62.8%), VPA 
(19.94%; male vs. female, 29.2% vs. 70.8%) and LTG (13.5%; male vs. female, 22.7% vs. 
77.3%). Most commonly, CBZ caused toxicoderma, hepatotoxicity (an increase of over 2 N 
[upper limit of the normal range] in one or combination of the following: ALT, AST, gamma-
GT and total bilirubin), dizziness, sleepiness, mild depression (with or without anxiety) and 
vomiting (or nausea). Similarly, VPA induced ADRs including weight gain, alopecia, tremor 
and hepatotoxicity and, infrequently, mild depression or anxiety. LTG-induced common 
ADRs were: toxicoderma and, rarely, mild depression or anxiety. OXC caused toxicoderma 
and dizziness. All other AEDs caused fewer than 5 symptoms. The occurrence of (usually 
mild) depression was 7% of all recorded ADRs. There was no suicidal attitude, behaviour or 
attack reported. 
A pharmacovigilance report of the most commonly used AEDs can be found in Tables 3 and 
4. All the patients having ever taken a certain AED according to out-patient files were 
included in the report. Surprisingly, newer AEDs (except LEV) showed higher values of PRR 
and ROR. 
 
Table 3 Number of patient events who have ever taken a certain drug characterised by PRR 
and ROR 
AED 
Number 
of 
patients 
PRR ROR 
12 
 
CBZ 1042 1.28 1.32 
CLB 43 1.03 1.03 
CLZ 135 0.25 0.23 
GPB 87 1.12 1.14 
LEV 173 0.75 0.73 
LTG 329 1.21 1.24 
OXC 156 1.02 1.02 
PHT 123 0.56 0.53 
PRM 52 0.85 0.83 
TPM 40 1.56 1.68 
VPA 547 1.06 1.07 
ZNS 19 2.35 2.83 
 
 
Comparing PRR and 95% CI of old (PRR: 0.86; 95% CI [0.67-1.05], χ2= 2.42, p=0.12) and 
new (PRR: 1.16; 95% CI [0.97-1.35], χ2= 2.42, p=0.12) generation AEDs, we found no 
significant superiority of newer AEDs. Table 4 contains the signal detection of Adverse Drug 
Reactions in accordance with the EMA criteria. 
Table 4 Signal detection of ADRs according to the EMA fulfilled criteria 
AED and ADR PRR Lower 95% CI χ2 p-value 
CBZ hepatotoxicity 4.63 3.87 19.57 <0.0001 
CBZ itching 10.22 8.15 7.55 0.006 
VPA tremor 4.06 3.0 7.7 0.006 
VPA weight gain 16.59 15.51 47.62 <0.0001 
VPA alopecia 6.1 5.14 17.43 <0.0001 
OXC dizziness 3.03 2.16 6.16 0.01 
GBP dizziness 3.73 2.81 7.52 0.006 
TPM somnolence 3.84 2.81 6.17 0.01 
 
 
3.4 Concomitant drugs acting on the CNS 
As Table 5 shows, 279 (22%) patients took concomitant drug(s) acting on the CNS. Although 
no gender-based difference was established within the “monotherapy” group concerning 
patients with or without seizures, significant differences were confirmed regarding either one 
(p= 0.03) or ≥2 (p= 0.03) certain other medicines acting on the CNS. Comparing the number 
of patients with or without CNS co-medication the difference was even more pronounced 
(p=0.003). 
There was a significant difference between all seizure free and all seizure-affected patients on 
AEDs taking two or more drugs acting on the CNS (p= 0.02). 
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Analysing and comparing all the patients who took at least one type of medicine acting on the 
CNS with the ones that did not, we found the difference was significant (p=0.009). 
Only 22 (8%) of the 279 patients were on psychoactive drugs which could alter the effects of 
AEDs, CBZ, LTG, PHT and VPA being the AEDs in the focus of attention.  
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Table 5 Antiepileptic therapy with or without concomitant drug therapy acting on the CNS 
Type of 
therapy and 
number of 
patients 
No. of 
other 
CNS 
drugs 
All 
patients 
All 
male 
Seizure 
free 
Male Not 
seizure 
free 
Male 
All 
female 
Female Female 
Monotherapy 
(894) 
0 
726 
(81.2%) 
348 
(47.9%) 394 
(54.3%) 
185 
(47%) 332 
(45.7%) 
163 
(49.1%) 
378 
(52.1%) 
209 
(53%) 
169 
(50.9%) 
1 
114 
(12.8%) 
56 
(49.1%) 
49 (43%) 
26 
(53.1%) 
65 (57%) 
30 
(46.2%) 
58 
(50.9%) 
23 
(46.9%) 
35 
(53.8%) 
≥2 54 (6%) 
23 
(42.6%) 21 
(38.9%) 
10 
(47.6%) 33 
(61.1%) 
13 
(39.4%) 
31 
(57.4%) 
11 
(52.4%) 
20 
(60.6%) 
Bitherapy 
(286) 
0 
209 
(73.1%) 
105 
(50.2%) 
81 (36%) 
42 
(52.4%) 128 
(64%) 
63 
(47.3%) 
104 
(49.8%) 
39 
(47.6%) 
65 
(52.7%) 
1 
54 
(18.9%) 
21 
(38.9%) 26 
(48.1%) 
10 
(38.5%) 28 
(51.9%) 
11 
(39.3%) 
33 
(61.1%) 
16 
(61.5%) 
17 
(60.7%) 
≥2 23 (8%) 
11 
(47.8%) 
8 (34.8%) 
4 (50%) 
15 
(65.2%) 
7 
(46.7%) 
12 
(52.2%) 
4 (50%) 
8 
(53.3%) 
Polytherapy 
(102) 
0 
68 
(66.7%) 
31 
(45.6%) 16 
(23.5%) 
7 
(43.8%) 52 
(76.5%) 
24 
(46.2%) 
37 
(54.4%) 
9 
(56.2%) 
28 
(53.8%) 
1 
26 
(25.5%) 
11 
(42.3%) 
7 (26.9%) 
5 
(71.4%) 19 
(73.1%) 
6 
(31.6%) 
15 
(57.7%) 
2 
(28.6%) 
13 
(68.4%) 
≥2 
8 
(7.8%) 
2 (25%) 
1 (12.5%) 
0 (0%) 
7 (87.5%) 
2 
(28.6%) 
6 (75%) 
1 
(100%) 
5 
(71.4%) 
N=1282 
0 
1003 
(78%) 
 603  679  
≥1 
279 
(22%) 
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4. Discussion 
4.1 Basic characteristics of patients 
Gender distribution was nearly equal if all patient groups were examined but, in the childhood 
onset groups, there was a remarkable difference by gender, women being in majority. The 
mean duration from the first epileptic seizure was 9.54 years despite the fact that 686 patients 
were diagnosed with new onset epilepsy during the 20 years’ study period. A probable 
explanation might be that our out-patient unit provides care only for adults, but approximately 
1/5 and 1/6 of patients had their first seizure in childhood or adolescence, respectively. 
There was not a second peak in the incidence of new onset seizures over 50 years of age, 
although, in adults, stroke was the most common cause of symptomatic epilepsy, which is 
quite common in this age group. 
In our database, the ratio of generalised epilepsy was higher than in the adult epileptic 
population with newly diagnosed epilepsy, but we registered and attended patients after 16 
years of age. 
Stroke and head injury followed by congenital disorders were the most common causes of 
symptomatic epilepsy. The great majority of these patients had focal seizures which evolved 
into bilateral convulsive seizures. 
Mortality rate was 6.9% primarily because of comorbidities. 
4.2 Treatment characteristics 
The choice of AEDs must be matched to the patient’s seizure type(s) and / or epilepsy 
syndrome, age, gender, childbearing potential, weight, psychiatric and other comorbidities, 
concomitant medications and lifestyle [21, 22]. In all cases, the above were taken into 
consideration, nevertheless sometimes the cost / price of drugs was also of concern. 
We found that most of the patients were on older AEDs such as CBZ, VPA and LTG; OXC 
and LEV belong to the family of newer AEDs. The drugs CBZ, VPA, LTG were prescribed 
either in generalized or focal seizures whereas OXC and LEV were administered only in focal 
seizures and in combination. 
In contrast with certain data in the literature, PHT and PB prescriptions were quite uncommon 
[23]. Newer AEDs (taken by 25.6% of patients) were indicated frequently in both 
monotherapy and bitherapy. 
One probable explanation for these differences in the literature might be that our epilepsy out-
patient unit provides care for patients from the age of 16 and our female patients were 
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potentially in adolescent or childbearing age which was also taken into consideration. The 
severe side effects of VPA, PHT and PB have been widely known. Another explanation for 
differences in the literature and our findings might be that some patients have comorbidities at 
the onset of epilepsy and there are a number of newly evolving disorders requiring a switch to 
a non–enzyme-inducing AED (e.g. cancer therapy, osteoporosis, hyperlipidemia, sexual 
dysfunction and infertility). In all these cases the best possible AED therapy was chosen 
considering pharmacokinetics and the ADR profile. 
A recent study reported 68% overall seizure freedom in generalized and partial seizure which 
was higher than our finding (50.5%) [24]. We did not find significant difference between 
patient groups with generalized and partial epilepsy (p=0.41). 
More than 30% of patients were given two or more AEDs. In our database, 24% of these 
patients were seizure free, which is slightly higher than the figure (20.5%) in a study by 
Stephen LJ et al [25]. 
In our database, VPA, an enzyme inhibitor, played the same role in mono-, bi-, and 
polytherapy. Almost one in five patients took an AED without enzymatic effect in the 
monotherapy group. In both of the bi-, and polytherapy groups, the second choice of AEDs 
was for enzyme inducers or inhibitors. Nowadays, in routine clinical practice first line AEDs 
should be used depending on the type of epilepsy but prior to prescribing of enzyme inducer 
AED, physicians should always consider interactions with co-medications (e.g. 
antidepressants, antipsychotics, cytostatics, antiretrovirals, statins, anticoagulants, oral 
contraceptives, immunosuppressant, analgesics, antihypertensives, etc.) [21]. 
Our data may confirm Brodie’s opinion that physicians should consider starting treatment 
with, or even switching patients to non–enzyme-inducing AEDs in order to avoid 
complications, particularly if the epilepsy is not fully controlled [26]. 
In our database, non-adherence to treatment in patients with epilepsy was better (12%) than in 
the report by Jones et al. in a cross-sectional study (59%) but we did not use special 
questionnaire scores comparing the patients with well and poorly controlled epilepsy [8]. 
4.3 Adverse drug reaction (ADR) and pharmacovigilance evaluation of AEDs 
Chronic use of AEDs may be associated with several adverse events with systemic effect and 
affecting the CNS. Furthermore, enzyme-inducing AEDs may contribute to the development 
of comorbidities. Modern AEDs that lack this property have similar efficacy in common 
epilepsies [21]. Quality of life and adherence to treatment depend on seizure control and the 
presence of ADRs [8]. 
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The incidence of self-reported ADRs was 16.2%, approximately half as much (36.5%) as the 
incidence rate in an Italian study; these patients had drug-refractory epilepsy and only less 
than a quarter of them received monotherapy [11]. We found that women reported ADRs 
more frequently than men did. It was especially unexpected among patients on monotherapy; 
the difference was significant. Female dominance (64%) concerning ADR rates could be 
attributed to genetic polymorphism [27]. 
In the database, we found that most of the patients were on older AEDs such as CBZ, VPA 
and PHT, and on LTG, LEV and OXC belong to newer AEDs. Although newer AEDs were 
considered more beneficial owing to the fewer ADRs they caused; except for LEV, our data 
suggested the same profile as that of the older ones. 
The results of PRR analysis of older versus newer AEDs with ADR were unexpected, they 
revealed no significant superiority of newer AEDs. The underlying cause of overreported 
ADRs regarding newer AEDs may have been associated with greater awareness to the newly 
marketed drugs and these drugs were introduced as add-on therapy. If a newly introduced 
drug was prescribed, patients’ education was much more thorough and the new drug was 
strictly monitored. 
Using PRR and χ2, SDR showed the association between drug-event pairs in the database. No 
unknown or new ADR was detected in our database. Only eight ADRs fulfilled the EMA 
criteria to report signal detection. Three out of eight were newer AEDs. Due to the relatively 
low number of cases, only the most common symptoms met the definition of SDR. 
4.4 Concomitant drugs acting on the CNS 
Psychiatric comorbidities are not infrequent in patients with epilepsy [28, 29]. Use of 
antidepressant and antipsychotic drugs is common in patients receiving enzyme-inducing 
AEDs [30]. We analysed and compared all the patients who took at least one medicine acting 
on the CNS with those who did not; there was a significant difference between the two 
groups. 
In our logistic regression model, we found that the number of AEDs and other drugs acting on 
the CNS affected seizure freedom and had a significant impact. Increase in the number of 
AEDs and the presence of other drugs acting on the CNS reduced the chance of seizure 
freedom significantly. 
The explanation of these results may be that these interactions are very complex and combine 
pharmacokinetic and pharmacodynamic processes [21, 31, 32, 33]. Although variations in the 
extent of induction may differ between CYPs, there must be common cellular signalling 
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mechanisms, nuclear receptors (glucocorticoid and oestrogen) may also participate in the 
induction of certain drugs; however, the transcription factors appear to be broadly involved in 
enzyme induction [34, 35]. 
AED doses were built up very carefully, probably that is why our patients had relatively fewer 
ADRs and interactions between AED(s) and concomitant drugs acting on the CNS. 
In clinical studies, researchers have demonstrated that the magnitude of induction of various 
CYP isoenzymes appears to be at least partially dependent upon the dose of the enzyme-
inducing drug [36]. 
We are aware, that our study has several limitations. First, our study is an observational study 
and not a randomized, controlled trial, therefore selection bias could have affected the results. 
Second, treatment options and definitions changed a lot during this 20-year-time period. 
Nevertheless, the advantage is prospective data collection and detailed information on all 
subjects can be regarded as an important advance in this field. Further strength of our study 
may be the real-life data sets leading to a better understanding of real-life clinical settings and 
the outcome of routine epilepsy treatment. 
5. Conclusion 
Based on our findings, we can conclude that careful drug selection for epileptic patients must 
be highlighted in order to improve the outcome of treatment, reduce ADRs and improve 
patient compliance, especially in female patients. The number of AEDs and other CNS related 
drugs can influence seizure freedom. 
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